Hodgkin’s Lymphoma

September 26, 2018

Adcetris, Chemo Combo Approved in Japan for Untreated, Advanced Hodgkin’s Lymphoma

News

The Japanese Ministry of Health, Labour and Welfare has approved the use of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for CD30-positive Hodgkin’s lymphoma patients ... Read more

September 21, 2018

Chemotherapy Used to Treat Hodgkin’s Lymphoma in Women Age 35 or Older Risks Damage to Ovaries, Study Finds

News

Damage to the ovaries is likely in women with Hodgkin’s lymphoma who are 35 years old or older and given standard chemotherapy, and in those at any age treated with BEACOPP chemotherapy, a secondary analysis ... Read more

September 11, 2018

Adcetris-Chemotherapy Combo Improves Survival Rates in Elderly Hodgkin’s Patients, Phase 2 Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly improves responses and survival rates of elderly patients with newly diagnosed Hodgkin’s lymphoma, a Phase 2 study shows. In the trial, 90% of ... Read more

September 6, 2018

New Drug Application for Investigational Hodgkin’s Lymphoma Therapy Tislelizumab Accepted in China

News

China’s regulatory agency recently accepted BeiGene’s new drug application (NDA) for tislelizumab, its investigational immune checkpoint inhibitor, for the potential treatment of patients with classical Hodgkin’s lymphoma who failed to respond or whose disease ... Read more

July 9, 2018

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

News

Sintilimab (IBI308), an immunotherapy candidate, was found to be safe and completely eliminated tumors in one-fourth of Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) treated in a Phase 2 ... Read more

June 27, 2018

Keytruda-AFM13 Combo Effective for Hodgkin’s Lymphoma, Preliminary Phase 1b Data Show

News

Treatment with Keytruda (pembrolizumab) and Affimed’s AFM13 is well-tolerated with a favorable response rate in patients with relapsed or refractory Hodgkin’s lymphoma, according to an early analysis of a Phase 1b trial. ... Read more

June 4, 2018June 1, 2018

Upon Hearing Those 3 Words: ‘You Have Cancer’

Columns, Life After Lymphoma: A Young Warrior's Guide to Recovery - a Column by Michelle Raphaella Fredman

It was Monday morning. The sun was shining and life was good. It was the start of what I’d assumed was going to be my best summer yet. I was ... Read more

May 10, 2018May 9, 2018

I’ve Seen the Impact of Cancer Research

Columns, Overcoming Adversity- a Column by Radiant Racheli

Before my cancer diagnosis, the only cancer organizations I knew of were some breast cancer charities and the Leukemia & Lymphoma Society (LLS). As someone who didn’t have cancer and wasn’t ... Read more

April 5, 2018April 5, 2018

Telo-HL Scoring Model Developed to Predict Relapse Risk in Hodgkin’s Patients, 3DS Says

News

3D Signatures’ Telo-HL test may be one step closer to clinical use with the development of a scoring model designed to predict the risk of relapse in Hodgkin’s lymphoma patients. The company ... Read more

March 20, 2018March 20, 2018

Rich’s RP-323 Shows Activity Against Hodgkin’s Lymphoma in Phase 1 Trial

News

Experimental therapy RP-323 has shown anticancer activity against Hodgkin’s lymphoma in a Phase 1 trial. Its developer, Rich Pharmaceuticals, is now planning to evaluate the therapy in human clinical trials for the disease. ... Read more